Daniel kisner (20 risultati)
Oxford Studies in Early Modern Philosophy: Volume V
Garber, Daniel; Steven Nadler; Kurt Smith; Alan Nelson; Christopher Martin; Herman De Dijn; Matthew Kisner; Matteo Favaretti Camposampiero; Samuel Levey; T. Allan Hillman; John Russell Roberts; Michael Jacovides
- Brossura
- Prima edizione
Da: Rosario Beach Rare Books, Lake Stevens, WA, U.S.A.Rosario Beach Rare Books
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Molto buono
EUR 51,99
Spedizione gratuitaSpedito in U.S.A.Quantità: 1 disponibili
Soft cover. Condizione: Very Good. 1st Edition. *Veteran-Owned, Family-Run, Small Book Store in the Pacific Northwest* FAST SHIPPING!! clean text, no markings, tight binding, front cover corner bumped.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Come nuovo
EUR 124,19
EUR 2,31 spedizioneSpedito in U.S.A.Quantità: 15 disponibili
Condizione: As New. Unread book in perfect condition.
Lingua: Inglese
Editore: Springer, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
Da: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Come nuovo
EUR 124,19
EUR 2,31 spedizioneSpedito in U.S.A.Quantità: 15 disponibili
Condizione: As New. Unread book in perfect condition.
Lingua: Inglese
Editore: Springer, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
Da: Ria Christie Collections, Uxbridge, Regno UnitoRia Christie Collections
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 115,35
EUR 14,06 spedizioneSpedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Condizione: New. In.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: Ria Christie Collections, Uxbridge, Regno UnitoRia Christie Collections
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 117,12
EUR 14,06 spedizioneSpedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Condizione: New. In.
Lingua: Inglese
Editore: Springer, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
Da: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 131,03
EUR 2,31 spedizioneSpedito in U.S.A.Quantità: 15 disponibili
Condizione: New.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: GreatBookPricesUK, Woodford Green, Regno UnitoGreatBookPricesUK
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 117,11
EUR 17,61 spedizioneSpedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Condizione: New.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: GreatBookPrices, Columbia, MD, U.S.A.GreatBookPrices
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 132,72
EUR 2,31 spedizioneSpedito in U.S.A.Quantità: 15 disponibili
Condizione: New.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: GreatBookPricesUK, Woodford Green, Regno UnitoGreatBookPricesUK
Contatta il venditoreVenditore con 5 stelleCondizione: Usato - Come nuovo
EUR 130,47
EUR 17,61 spedizioneSpedito da Regno Unito a U.S.A.Quantità: Più di 20 disponibili
Condizione: As New. Unread book in perfect condition.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: Books Puddle, New York, NY, U.S.A.Books Puddle
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 162,38
EUR 3,49 spedizioneSpedito in U.S.A.Quantità: 4 disponibili
Condizione: New. pp. 128.
Lingua: Inglese
Editore: Springer US, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 112,77
EUR 61,04 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Taschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular a…nd subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.
Lingua: Inglese
Editore: Springer US, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: moluna, Greven, Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 128,20
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: Più di 20 disponibili
Gebunden. Condizione: New. Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone .
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: Mispah books, Redhill, SURRE, Regno UnitoMispah books
Contatta il venditoreVenditore con 4 stelleCondizione: Usato - Molto buono
EUR 187,38
EUR 29,34 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 1 disponibili
Hardcover. Condizione: Very Good. Very Good. book.
Lingua: Inglese
Editore: Springer Nature B.V. Apr 1985, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
Da: AHA-BUCH GmbH, Einbeck, GermaniaAHA-BUCH GmbH
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 157,87
EUR 61,81 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Buch. Condizione: Neu. Neuware - Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intramus cular and subcutaneous routes. Clinical toxicity principa…lly involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.
Lingua: Inglese
Editore: Springer, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
- Print on Demand
Da: Brook Bookstore On Demand, Napoli, NA, ItaliaBrook Bookstore On Demand
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 86,24
EUR 4,00 spedizioneSpedito da Italia a U.S.A.Quantità: Più di 20 disponibili
Condizione: new. Questo è un articolo print on demand.
Lingua: Inglese
Editore: Springer US Okt 2011, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
- Print on Demand
Da: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermaniaBuchWeltWeit Ludwig Meier e.K.
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 117,65
EUR 23,00 spedizioneSpedito da Germania a U.S.A.Quantità: 2 disponibili
Taschenbuch. Condizione: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous,…intramus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated. 128 pp. Englisch.
Lingua: Inglese
Editore: Springer US, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
- Print on Demand
Da: moluna, Greven, Germaniamoluna
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 92,27
EUR 48,99 spedizioneSpedito da Germania a U.S.A.Quantità: Più di 20 disponibili
Condizione: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Proceedings of the Symposium held in Adjunction with the Second International Conference on Malignant Lymphoma, Lugano, Switzerland, June 13, 1984 Interferon alpha-2 is a genetically engineered, highly purified pharm…aceutical agent that has undergone .
Lingua: Inglese
Editore: Springer, Springer Okt 2011, 2011
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Brossura
- Print on Demand
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germaniabuchversandmimpf2000
Contatta il venditoreVenditore con 5 stelleCondizione: Nuovo
EUR 106,99
EUR 60,00 spedizioneSpedito da Germania a U.S.A.Quantità: 1 disponibili
Taschenbuch. Condizione: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Interferon alpha-2 is a genetically engineered, highly purified pharmaceutical agent that has undergone extensive phase I and phase II clinical study in more than 1000 patients. The material has biological activity by intravenous, intr…amus cular and subcutaneous routes. Clinical toxicity principally involves the 'influen za like' syndrome previously seen with native interferons. Other important toxi cities include anorexia, hepatitis, confusion and myelosuppression. Tolerable doses in multiple schedules and routes of administration have been determined. Phase II clinical trials with multiple routes and schedules of administration have been performed. Significant clinical activity has been found in non Hodgkin's lymphomas (both low grade and high grade), refractory and relapsing multiple myeloma, hairy cell leukemia, Kaposi's sarcoma, with suggestions of activity in Hodgkin's disease, renal cell carcinoma, and melanoma. The studies performed to date have for the most part involved small numbers of heavily pre-treated patients. Large-scale clinical trials in some of these disea ses are now warranted in populations of patients with as little bulk disease and prior treatment as is feasible for each tumour type. This is particularly the case in . Hodgkin's disease and subcategories of the non-Hodgkin's lymphomas. Alterna tely, interferon alpha-2 might be used to maintain remissions induced by other modalities (i. e. , in NHL, multiple myeloma, ovarian cancer). In some advanced disease settings, combinations of interferon alpha-2 with chemotherapeutic agents should now be investigated.Springer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 128 pp. Englisch.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
- Print on Demand
Da: Majestic Books, Hounslow, Regno UnitoMajestic Books
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 170,76
EUR 7,63 spedizioneSpedito da Regno Unito a U.S.A.Quantità: 4 disponibili
Condizione: New. Print on Demand pp. 128 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam.
Lingua: Inglese
Editore: Springer, 1985
Serie: Developments in Oncology, Libro 75 di 78. Libro 75 di 78 - Developments in Oncology
- Rilegato
- Print on Demand
Da: Biblios, frankfurt am main, HESSE, GermaniaBiblios
Contatta il venditoreVenditore con 4 stelleCondizione: Nuovo
EUR 170,92
EUR 9,95 spedizioneSpedito da Germania a U.S.A.Quantità: 4 disponibili
Condizione: New. PRINT ON DEMAND pp. 128.
